Harmony Biosciences Holdings, Inc. (HRMY)

Market Cap	1.85B
Revenue (ttm)	744.85M
Net Income (ttm)	152.72M
Shares Out	57.42M
EPS (ttm)	2.62
PE Ratio	12.27
Forward PE	10.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	287,680
Open	32.30
Previous Close	32.11
Day's Range	31.87 - 32.42
52-Week Range	26.47 - 41.61
Beta	0.83
Analysts	Strong Buy
Price Target	54.22 (+68.6%)
Earnings Date	Aug 5, 2025

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 19, 2020
• Employees: 268
• Stock Exchange: NASDAQ
• Ticker Symbol: HRMY
• Website: https://www.harmonybiosciences.com

Financial Performance

In 2024, HRMY's revenue was $714.73 million, an increase of 22.80% compared to the previous year's $582.02 million. Earnings were $145.49 million, an increase of 12.91%.

Analyst Summary

According to 9 analysts, the average rating for HRMY stock is "Strong Buy." The 12-month stock price target is $54.22, which is an increase of 68.60% from the latest price.

Price Target

$54.22

(68.60% upside)

Analyst Consensus: Strong Buy